The RSV Vaccine Population was Narrowed for Good Reason, says Robert Hopkins, Jr, MD, Medical Director of the NFID

Recommendations for adult vaccination against respiratory syncytial virus (RSV) have fluctuated since the first vaccine became available in 2023. Most recently, in early summer, the Advisory Committee on Immunization Practices (ACIP) to the US CDC "tightened the recommendations [around] the groups that are likely to get the greatest benefit" from the immunization, Robert Hopkins, Jr, MD, medical director of the National Foundation of Infectious Diseases, explained in an interview with Patient Care.

In the short video above, Hopkins explains the shift in population emphasis by the ACIP between June 2023 and June 2024, with the recommendation for a single lifetime dose raised from all adults aged 60 years and older to all adults aged 75 years and older, with adults in the 60-to-74-year-old population eligible if they are at increased risk of becoming severely ill.